# Phase II Biomarker Study Comparing the Combination of BRAF Inhibitor Dabrafenib With MEK Inhibitor Trametinib Versus the Combination After Monotherapy With Dabrafenib or Trametinib

> **NCT02314143** · PHASE2 · TERMINATED · sponsor: **GlaxoSmithKline** · enrollment: 48 (actual)

## Conditions studied

- Melanoma

## Interventions

- **DRUG:** Dabrafenib
- **DRUG:** Trametinib

## Key facts

- **NCT ID:** NCT02314143
- **Lead sponsor:** GlaxoSmithKline
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2013-11-13
- **Primary completion:** 2017-01-19
- **Final completion:** 2017-01-19
- **Target enrollment:** 48 (ACTUAL)
- **Why stopped:** The study was terminated early due to slow enrollment and limited numbers of viable tissue samples.
- **Last updated:** 2019-02-18


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02314143

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02314143, "Phase II Biomarker Study Comparing the Combination of BRAF Inhibitor Dabrafenib With MEK Inhibitor Trametinib Versus the Combination After Monotherapy With Dabrafenib or Trametinib". Retrieved via AI Analytics 2026-07-26 from https://api.ai-analytics.org/clinical/NCT02314143. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*